These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 36445243)

  • 21. Current approaches to enhance CNS delivery of drugs across the brain barriers.
    Lu CT; Zhao YZ; Wong HL; Cai J; Peng L; Tian XQ
    Int J Nanomedicine; 2014; 9():2241-57. PubMed ID: 24872687
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A hybrid siRNA delivery complex for enhanced brain penetration and precise amyloid plaque targeting in Alzheimer's disease mice.
    Zheng X; Pang X; Yang P; Wan X; Wei Y; Guo Q; Zhang Q; Jiang X
    Acta Biomater; 2017 Feb; 49():388-401. PubMed ID: 27845275
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In Vivo Genome Editing Restores Dystrophin Expression and Cardiac Function in Dystrophic Mice.
    El Refaey M; Xu L; Gao Y; Canan BD; Adesanya TMA; Warner SC; Akagi K; Symer DE; Mohler PJ; Ma J; Janssen PML; Han R
    Circ Res; 2017 Sep; 121(8):923-929. PubMed ID: 28790199
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current advances in delivery of biotherapeutics across the blood-brain barrier.
    Rajadhyaksha M; Boyden T; Liras J; El-Kattan A; Brodfuehrer J
    Curr Drug Discov Technol; 2011 Jun; 8(2):87-101. PubMed ID: 21513485
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nanoparticles-based delivery system and its potentials in treating central nervous system disorders.
    Liu T; Xie Q; Dong Z; Peng Q
    Nanotechnology; 2022 Aug; 33(45):. PubMed ID: 35917704
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epigenome Editing in the Brain.
    Bashtrykov P; Jeltsch A
    Adv Exp Med Biol; 2017; 978():409-424. PubMed ID: 28523558
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel blood-brain barrier co-culture system for drug targeting of Alzheimer's disease: establishment by using acitretin as a model drug.
    Freese C; Reinhardt S; Hefner G; Unger RE; Kirkpatrick CJ; Endres K
    PLoS One; 2014; 9(3):e91003. PubMed ID: 24608847
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting nanoparticles across the blood-brain barrier with monoclonal antibodies.
    Loureiro JA; Gomes B; Coelho MA; do Carmo Pereira M; Rocha S
    Nanomedicine (Lond); 2014 Apr; 9(5):709-22. PubMed ID: 24827845
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced BBB permeability of osmotically active poly(mannitol-co-PEI) modified with rabies virus glycoprotein via selective stimulation of caveolar endocytosis for RNAi therapeutics in Alzheimer's disease.
    Park TE; Singh B; Li H; Lee JY; Kang SK; Choi YJ; Cho CS
    Biomaterials; 2015 Jan; 38():61-71. PubMed ID: 25457984
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gene Therapy for Drug-Resistant Glioblastoma via Lipid-Polymer Hybrid Nanoparticles Combined with Focused Ultrasound.
    Yang Q; Zhou Y; Chen J; Huang N; Wang Z; Cheng Y
    Int J Nanomedicine; 2021; 16():185-199. PubMed ID: 33447034
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A physiologically-based pharmacokinetic model to describe antisense oligonucleotide distribution after intrathecal administration.
    Monine M; Norris D; Wang Y; Nestorov I
    J Pharmacokinet Pharmacodyn; 2021 Oct; 48(5):639-654. PubMed ID: 33991294
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted delivery of nano-therapeutics for major disorders of the central nervous system.
    Gao H; Pang Z; Jiang X
    Pharm Res; 2013 Oct; 30(10):2485-98. PubMed ID: 23797465
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nanocarrier-based therapies for CNS tumors.
    Patel TR
    CNS Oncol; 2014 Mar; 3(2):115-22. PubMed ID: 25055017
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Delivering the Promise of Gene Therapy with Nanomedicines in Treating Central Nervous System Diseases.
    Luo M; Lee LKC; Peng B; Choi CHJ; Tong WY; Voelcker NH
    Adv Sci (Weinh); 2022 Sep; 9(26):e2201740. PubMed ID: 35851766
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Next Generation Precision Medicine: CRISPR-mediated Genome Editing for the Treatment of Neurodegenerative Disorders.
    Raikwar SP; Kikkeri NS; Sakuru R; Saeed D; Zahoor H; Premkumar K; Mentor S; Thangavel R; Dubova I; Ahmed ME; Selvakumar GP; Kempuraj D; Zaheer S; Iyer SS; Zaheer A
    J Neuroimmune Pharmacol; 2019 Dec; 14(4):608-641. PubMed ID: 31011884
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting neuroinflammation by intranasal delivery of nanoparticles in neurological diseases: a comprehensive review.
    Moradi F; Dashti N
    Naunyn Schmiedebergs Arch Pharmacol; 2022 Feb; 395(2):133-148. PubMed ID: 34982185
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nucleic acid therapies for CNS diseases: Pathophysiology, targets, barriers, and delivery strategies.
    Padmakumar S; D'Souza A; Parayath NN; Bleier BS; Amiji MM
    J Control Release; 2022 Dec; 352():121-145. PubMed ID: 36252748
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CRISPR/Cas9 novel therapeutic road for the treatment of neurodegenerative diseases.
    Karimian A; Gorjizadeh N; Alemi F; Asemi Z; Azizian K; Soleimanpour J; Malakouti F; Targhazeh N; Majidinia M; Yousefi B
    Life Sci; 2020 Oct; 259():118165. PubMed ID: 32735884
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genome Editing with AAV-BR1-CRISPR in Postnatal Mouse Brain Endothelial Cells.
    Song X; Cui Y; Wang Y; Zhang Y; He Q; Yu Z; Xu C; Ning H; Han Y; Cai Y; Cheng X; Wang J; Teng Y; Yang X; Wang J
    Int J Biol Sci; 2022; 18(2):652-660. PubMed ID: 35002515
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cre Fused with RVG Peptide Mediates Targeted Genome Editing in Mouse Brain Cells In Vivo.
    Zou Z; Sun Z; Li P; Feng T; Wu S
    Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27983648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.